Navigation Links
Wyeth's Torisel and Roche/Genentech's Avastin Will Challenge Pfizer's Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
Date:8/19/2007

Increased Survival Rates and Decreased Disease Progression Rates Are the

Advantages, According to a New Report from Decision Resources

WALTHAM, Mass., Aug. 7 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Wyeth's Torisel and Roche/Genentech's Avastin will challenge Pfizer's Sutent as the clinical gold standard for the treatment of metastatic renal cell carcinoma. According to the new report entitled Two Hot New Drugs Battle for Top Position: A Renal Cell Carcinoma Study, both Torisel and Avastin offer increased overall survival rates as well as decreased disease progression times.

"Metastatic renal cell carcinoma is an end-stage disease in which the primary goal of treatment is to prolong survival," said Mohamed Muhsin, analyst at Decision Resources. "Phase III clinical trials have shown Torisel to increase the median overall survival rates of patients by 49 percent. High rates of partial response and stable disease, extended median time to progression, and overall survival rates for patients on Torisel are promising. Phase II trials for Avastin have shown that 61% of patients had stable disease. The median progression-free survival rate was eleven months, and the one-year progression-free survival rates for patients with objective response, minor response, and stable disease were 80%, 57% and 27%, respectively."

About Two Hot New Drugs Battle for Top Position: A Renal Cell Carcinoma Study

Two Hot New Drugs Battle for Top Position: A Renal Cell Carcinoma Study covers the current and future state of the metastatic renal cell carcinoma drug market. The report includes the following:

-- More than 3,000 physician responses that define drug attributes that

drive prescription now and in the future.

* Clinical end point tradeoffs that are most influential to

physicians.

* Areas of unmet need with highest potential.

* Benchmark trial results for specific drug opportunities.

* Patient share potential for emerging therapies and target product

profiles.

-- Decision Resources proprietary analysis of commercial factors that

accelerate or constrain a drug's market potential.

* Promotion: DTC spend, detailing intensity.

* Reimbursement: formulary tier, prior approval restriction, quantity

limits.

* Labeling: black box warnings, approved patient segments,

contraindications.

* Competition: order of entry, pricing, generic entry, pipeline sales

forecast.

* Medical practice: decision trees, treating physician type, line of

therapy.

-- Comparisons of the key clinical attributes of current and emerging

therapies in the areas of efficacy, safety, and delivery.

-- Analysis and supporting data that identifies the clinical "Gold

Standard" now and over the next ten years.

-- Key insights as to which clinical end points have the greatest

influence on physician decision-making.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
2. FDA MedWatch: Avastin (bevacizumab) and Formation of Tracheoesophageal Fistula in a Recent Clinical Study in Patients with Limited-stage Small Cell Lung Cancer
3. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
4. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
5. Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
6. Annual Meeting of the Consortium of Multiple Sclerosis Centers Focuses on the Challenges of Care and Research in Multiple Sclerosis
7. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
8. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
9. Novavax Reports Positive Pre-Clinical Study Results from Live Virus Challenge to Pandemic Flu Vaccine
10. LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic Protection Against Influenza Challenge With Virus-Like Particle Immunization
11. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/10/2017)... K. Burchfield, DPM, is recognized by Continental Who,s Who as a ... Alabama . Dr. Burchfield serves as ... over 20 years of experience, as well as expertise in the ... "The podiatry professional ... to welcome you to his practice," the company,s website states. "We ...
(Date:6/8/2017)... --  Responding to Heath Ledger,s father,s recent call ... Chris Cornell in May, the mental health watchdog ... online psychiatric drug side effects search engine ... drug risks. The father of the late ... overdose, has called for tighter rules on prescription drugs. Speaking ...
(Date:6/7/2017)... Infusion Group, a brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has ... location. The Iowa facility ... cleanroom—the standard needed to compound intravenous (IV) nutrition formulations. A cleanroom ... "Our new cleanroom will allow us ... Iowa patients," said Phil Rielly , Diplomat ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... American Farmer, will feature ... which is slated to air fourth quarter 2017. American Farmer airs Tuesdays at 8:30aET ... a Danish pharmacist, founded Chr. Hansen in Denmark in 1874 after a groundbreaking discovery ...
(Date:6/23/2017)... Morgantown, WV (PRWEB) , ... June 23, 2017 ... ... asset protection services and personal financial planning to families and business owners in ... Stepping Stones organization to help provide services to differently abled residents in the ...
(Date:6/22/2017)... , ... June 22, 2017 , ... Groove Ring is ... word about their high performance silicon wedding bands and all-purpose rings. Whether you’re an ... active, silicone rings designed just for you. , From the rock face to the ...
(Date:6/22/2017)... ... 2017 , ... A June 12 article in The Star offers ... lack of oral hygiene by an aged parent who had recently suffered a series ... number of steps, including scheduling a dentist visit. Northridge Dental Works, a Los Angeles ...
(Date:6/20/2017)... ... June 20, 2017 , ... After months of negotiations, FaceCradle USA is proud to announce the ... June 21. , “Introducing our product on QVC is something we all worked hard to ... pillow to more than 90 million homes in the United States,” said FaceCradle USA President ...
Breaking Medicine News(10 mins):